1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Sinopharm Group Co., Ltd. Class H

Sinopharm Group Co., Ltd. Class H

15.40
HKD
-0.27
(-1.72%)
60.67BMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
66.13
77.41
82.63
93.53
103.75
116.09
143.11
146.7
167.48
176.93
191.17
187.3
184.31
- -
Basic EPS, GAAP
0.89
1.11
1.36
1.68
1.88
1.97
2.1
2.31
2.49
2.73
2.9
2.26
2.29
- -
Free Cash Flow per Basic Share
1.44
1.42
4.38
2.86
0.32
0.08
5.46
2.91
2.27
5.94
4.75
3.07
4.01
- -
Dividend per Share
0.25
0.26
0.31
0.41
0.47
0.53
0.59
0.6
0.69
0.75
0.82
0.87
0.68
- -
Book Value per Share
8.49
9.9
10.88
11.5
13.84
14.41
15.96
18.06
19.83
21.81
23.9
25.28
26.9
26.9
Tangible Book Value per Share
6.31
7.6
8.45
9.23
11.22
11.89
12.32
14.04
15.92
17.96
20.04
21.76
23.65
23.65
Basic Weighted Avg Shares
2,523
2,585
2,767
2,760
2,965
2,968
2,972
3,111
3,111
3,121
3,121
3,121
3,121
3,121
Sales/Revenue/Turnover
166,866
200,131
228,633
258,117
307,666
344,526
425,273
456,415
521,051
552,148
596,570
584,508
575,168
- -
Operating Margin (%)
3.66
3.93
4.02
3.85
4.05
4.57
4.35
4.33
4.03
4.08
3.73
3.04
2.97
- -
Depreciation Expense
677
835
1,006
1,068
1,240
1,395
3,114
3,597
3,922
4,165
4,430
4,734
4,289
- -
Net Income, GAAP
2,250
2,875
3,772
4,647
5,576
5,836
6,253
7,187
7,759
8,526
9,054
7,050
7,155
- -
Effective Tax Rate (%)
22.53
23.3
23.14
22.78
22.82
22.96
22.82
22.44
23.16
22.72
23.07
25.55
26.79
- -
Profit Margin (%)
1.35
1.44
1.65
1.8
1.81
1.69
1.47
1.57
1.49
1.54
1.52
1.21
1.24
- -
Working Capital
18,872
24,253
22,278
33,022
38,188
44,580
51,575
63,633
71,616
84,443
95,344
97,072
100,070
100,070
LT Debt
4,134
4,223
608
11,135
5,594
5,019
11,470
12,162
11,669
14,957
17,255
11,897
6,141
6,141
Total Equity
28,611
36,290
40,879
44,532
57,947
68,276
76,939
89,947
99,654
110,069
120,319
126,687
134,160
134,160
Return on Invested Capital (%)
10.04
9.96
10.39
10.57
11.52
9.75
9.59
9.33
9.12
9
8.18
5.99
5.68
- -
Return on Capital (%)
4.87
4.82
5.03
5.38
5.36
4.24
3.56
3.4
3.27
3.12
2.87
2.88
2.53
- -
Return on Common Equity (%)
11.51
11.69
13.12
15.01
15.9
14.39
13.86
13.85
13.12
13.12
12.69
9.19
8.79
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
64,490
87,521
64,820
LT Borrowings
8,637
4,436
3,645
LT Finance Leases
3,259
2,945
2,495
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,121
3,121
3,121
Market Capitalization
62,459
52,345
54,512

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
347,448
375,194
346,796
Cash, Cash Equivalents & STI
54,314
35,238
48,796
Accounts Receivable, Net
187,635
235,340
194,613
Inventories
62,353
66,814
63,341
Total Current Liabilities
250,376
279,850
246,726
Payables & Accruals
- -
- -
- -
ST Debt
64,490
87,521
64,820
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.82%
8.35%
5.9%
Free Cash Flow
627.68%
23.21%
30.73%
Net Income, GAAP
7.33%
0.68%
1.5%
Sales/Revenue/Turnover
9.94%
4.91%
-1.6%
Total Cash Common Dividend
10.35%
3.55%
-21.84%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
596,570
2024
- -
- -
584,508
2025
- -
- -
575,168

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.9
2024
- -
- -
2.26
2025
- -
- -
2.29

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.82
2024
- -
- -
0.87
2025
- -
- -
0.68

Company Description

Company Profile APIChatGPT
CEO
Wanyong Lian
Full Time Employees
94,910
Sector
Distribution services
Industry
Medical distributors
Address
Sinopharm Group Building Shanghai SH China 200023
IPO Date
Sep 23, 2009
Website
sinopharmgroup.com.cn
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Sinopharm Group Co. Ltd. engages in pharmaceutical supply chain services with primary operations in the People's Republic of China. The company operates through four main segments: Pharmaceutical Distribution; Medical Devices Distribution; Retail Pharmacy; and Other Business. Its Pharmaceutical Distribution segment focuses on the distribution of a wide range of pharmaceutical products to hospitals, distributors, retail pharmacies, and clinics, leveraging an extensive logistics network for warehousing and transportation. The Medical Devices segment distributes diverse medical devices including diagnostic equipment, surgical instruments, and patient monitoring systems, providing installation and maintenance services. The Retail Pharmacy segment manages and franchises a national network of retail drug stores, offering medications and health products directly to consumers. The Other Business segment encompasses pharmaceutical manufacturing, chemical reagents, laboratory supplies, medical instruments, traditional Chinese medicines, IT services, property management, and consulting. Sinopharm operates with a strong focus on therapeutic areas such as oncology, cardiology, infectious diseases, orthopedics, and radiology, impacting patient outcomes through access to essential medicines and advanced medical technologies. The company provides value-added services encompassing supply chain optimization, inventory management, healthcare consultation, and technology integration. Founded in 2003 and headquartered in Shanghai, Sinopharm is a subsidiary of Sinopharm Industrial Investment Co., Ltd. and maintains extensive relationships with domestic and international manufacturers and healthcare providers. In 2024, Sinopharm reinforced its strategic collaborations by signing a strategic cooperation agreement with Fresenius Kabi (China) Co. Ltd., a partnership dating back to 1982. These agreements aim to expand cooperation in pharmaceutical sales, warehousing, distribution, healthcare, medical care, and wellness sectors, enhancing service quality and product availability within China. The alliance is intended to foster innovation, strengthen supply chain capabilities, and support the development of the medical and health industry both domestically and globally. Recent advancements include the commercialization of new drug therapies developed by affiliated entities and approval for clinical trials of innovative vaccines such as the herpes zoster mRNA vaccine. Sinopharm's operations are bolstered by advanced logistics, supply chain management technologies, regulatory compliance, and ongoing expansion of its product portfolio and retail network, positioning it as a leading pharmaceutical distributor and healthcare services provider in China.

Company News

Company News APIChatGPT

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDY) and Pediatrix Medical Group (NYSE:MD) Financial Survey

  • accessnewswire.com

    Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Passes Above 50 Day Moving Average – Time to Sell?

  • prnewswire.com

    Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

  • prnewswire.com

    Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts

  • seekingalpha.com

    Pandemic Accelerates China's Drive Into mRNA Treatments

  • seekingalpha.com

    Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

  • seekingalpha.com

    Diversifying Into Top-Ranked Sinopharm

  • seekingalpha.com

    Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines

  • seekingalpha.com

    Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs